BiotechTube

Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scalp Psoriasis

Conditions

Scalp Psoriasis

Trial Timeline

Oct 20, 2017 → Oct 25, 2018

NCT ID
NCT03331523

About Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo

Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03331523. Target conditions include Scalp Psoriasis.

What happened to similar drugs?

0 of 5 similar drugs in Scalp Psoriasis were approved

Approved (0) Terminated (0) Active (5)
🔄PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
🔄DSXS + PlaceboSun PharmaceuticalPhase 3
🔄DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
🔄Secukinumab 300 mg + PlaceboNovartisPhase 3
🔄Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03331523Phase 3Completed

Competing Products

7 competing products in Scalp Psoriasis

See all competitors
ProductCompanyStageHype Score
DSXS topical productSun PharmaceuticalPhase 2
35
PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
40
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
40
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspensionSun PharmaceuticalPhase 1
29
Secukinumab 300 mg + PlaceboNovartisPhase 3
40
Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3
34